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Aims: To evaluate the effect of non‐dispensing pharmacists (NDPs) integrated in
general practice on medication‐related hospitalisations, drug burden index and costs
in patients at high risk of medication problems (being 65 years or older and using 5
or more chronic medications).
Methods: This was a multicentre, nonrandomised, controlled intervention study
with pre–post comparison (2013 vs June 2014 to May 2015) in 25 general practices
in the Netherlands, comparing NDP‐led care (intervention) with 2 current pharma-
ceutical care models (usual care and usual care plus). In the intervention group, 10
specially trained NDPs were employed in general practices to take integral responsi-
bility for the pharmaceutical care. They provided a broad range of medication
therapy management services both on patient level (e.g. clinical medication review)
and practice level (e.g. quality improvement projects). In the control groups,
pharmaceutical care was provided as usual by general practitioners and community
pharmacists, or as usual plus, when pharmacists were additionally trained in
performing medication reviews.
Results: Overall, 822 medication‐related hospitalisations were identified among
11 281 high‐risk patients during the intervention period. After adjustment for cluster-
ing and potential confounders, the rate ratio of medication‐related hospitalisations in
the intervention group compared to usual care was 0.68 (95% confidence interval:
0.57–0.82) and 1.05 (95% confidence interval: 0.73–1.52) compared to usual care
plus. No differences in drug burden index or costs were found.
Conclusions: In general practices with an integrated NDP, the rate of medication‐
related hospitalisations is lower compared to usual care. No differences with usual
care plus were found.
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1 | INTRODUCTION
With the aging of the population, the number of patients with comor-
bidities and polypharmacy increases.1 These elderly patients are
especially prone to unsafe and ineffective pharmacotherapy, leading
to adverse events and hospitalisations. In the Netherlands, 10.4% of
acute hospitalisations in elderly patients in 2013 were related to
medication and almost half of these hospitalisations were potentially
preventable.2
Pharmacists can have an important contribution to safe and effec-
tive pharmacotherapy, but at present they cannot optimally fulfil this
role. Several barriers are identified: pharmacists often do not have
access to patient medical records and generally, they are insufficiently
trained in clinical knowledge and consultation skills. Also, collaborative
working relationships between pharmacists and general practitioners
(GPs) are often suboptimal, despite working in the same geographical
area. The workload of both GPs and pharmacists also contributes to
a lack of focus on improving the quality of pharmaceutical care.3,4 Full
integration of a clinical non‐dispensing pharmacist (NDP) in the primary
care team could help to overcome these barriers.
Internationally, the role of pharmacists is developing from mainly
dispensing medication towards providing pharmaceutical care in a
clinical context.5 In this new role, the clinical pharmacist takes overall
responsibility for the patient's pharmacotherapy in close collaboration
with the treating physician.6 This new model of pharmaceutical
care provision includes different pharmacist‐led services, such as
performing clinical medication reviews, conducting quality improve-
ment projects, holding individual consultations for specific drug
therapy problems and educating team members in pharmacotherapy.
Pharmacist‐led services provided in general practice are demon-
strated to reduce the number of drug therapy problems and improve
intermediate outcomes, such as blood pressure, cholesterol and blood
glucose.7 So far, evidence on the effectiveness in terms of clinical out-
comes such as morbidity or mortality is lacking. We conducted the
POINT‐study8 (Pharmacotherapy Optimisation through Integration of
a non‐dispensing pharmacist in a primary care Team), to assess the
effect of integration of an NDP in general practice on medication‐
related hospitalisations. As secondary outcomes, we assessed the
effect on drug burden index (DBI) and costs.
2 | METHODS
A multicentre, nonrandomised, pragmatic, controlled intervention
study with pre–post comparison was conducted between January
2013 and June 2015, comparing pharmaceutical care by an NDP as
integral member of the primary care team (intervention group) with
2 current models of pharmaceutical care (control groups). For a
detailed description of the study design, see the study protocol.8
2.1 | Setting
This study was conducted in general practice in the Netherlands.
Participating practices were affiliated to 1 of 3 research networks:
Julius General Practitioners Network (University Medical Centre
Utrecht), healthcare network Almere (Zorggroep Almere) and the
Registration Network of General Practitioners Associated with Leiden
University (RNUH‐LEO).9-11
2.2 | Participating practices
For the intervention group, we included practices that were explicitly
willing to host an NDP. These practices had to meet the following
additional criteria: availability of a consultation room for the NDP;
access to the GPs' electronic medical records; a minimum of 5000 reg-
istered patients; at least 1 practice nurse working on chronic disease
management programmes.
For the control groups, we included practices that matched the
characteristics of practices in the intervention group as much as possi-
ble with regard to practice size, degree of urbanisation, socioeconomic
status and patients' age distribution.
2.3 | The intervention group: NDP‐led care
Ten NDPs (all PharmD) were embedded in 10 general practices in
the intervention group, on a full‐time basis. Concurrently, they
What is already known about this subject
• Elderly patients with polypharmacy are at risk of
medication‐related morbidity and mortality.
• Non‐dispensing pharmacists integrated in general
practice are reported to improve safety and
effectiveness of pharmacotherapy in single diseases and
proxy endpoints.
What this study adds
• This study demonstrates a lower risk on medication‐
related hospitalisations in patients with nondispending
pharmacist‐led care compared to usual care.
• To optimise the quality of pharmacotherapy,
pharmaceutical care needs to be fully integrated in
primary care.
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participated in a newly developed 15‐month Clinical Pharmacy
Training Program based on interprofessional workplace learning.12
The NDPs were given integral responsibility for the pharmaceutical
care in the practice, with a main focus on high‐risk patients: patients
aged 65 years or older and using 5 or more chronic medications.13
At the patient level, the NDPs performed clinical medication reviews
for patients with polypharmacy, medication reconciliations for patients
discharged from the hospital and individual patient consultations for
patients with specific drug therapy problems. Patients were either
invited by the NDPs, referred by the GPs or could consult on their
own request. At the practice level, the NDPs organised quality
improvement projects to systematically identify and treat patients at
risk of medication errors, and educated GPs and staff members on
pharmacotherapy.
In addition to these predefined fixed tasks, the NDPs' responsibil-
ities could be tailored to the specific needs of the practices. During the
Clinical Pharmacy Training Program, alignment to the predefined tasks
was evaluated and discussed regularly to increase fidelity of the inter-
vention. No modifications to the original predefined tasks were made.
2.4 | The control groups: usual care and usual care
plus
The usual care group consisted of general practices where pharmaceu-
tical care was provided in the traditional way, i.e. in collaboration with
community pharmacists. In the usual care plus group, pharmaceutical
care was provided in collaboration with community pharmacists who
had completed a nationally accredited training programme in
performing medication reviews.14,15
2.5 | Data collection
Data were collected between 2013 and 2015. The period between 1
January 2013 and 31 December 2013 served as baseline period
(pre).8 The intervention period started on 1 June 2014 and ended on
31 May 2015 (post). Three months prior to the intervention period,
NDPs already started working in the practices. These months were
considered necessary for the NDPs to learn basic clinical skills and
to establish their position in the practice16; no data were collected in
these months. For outcome measurements, we only included high‐risk
patients.
Patient characteristics, such as patients' medical history, medica-
tion records and laboratory results, were extracted anonymously from
the GPs' electronic medical records. The number of chronic conditions
was based on a standardised morbidity index list17 and a national
prevalence list18 of chronic diseases and multimorbidity. Data on
acute, unplanned hospitalisations in above described periods were
collected by research assistants. They visited participating practices
to collect anonymised discharge letters of acute hospitalisations. Data
from the GPs' electronic medical records were used for the analyses of
medication‐related hospitalisations and drug burden index. For the
cost‐analyses, anonymised healthcare cost reimbursement data from
the major health insurance company19 were used.
2.6 | Primary outcome
The primary outcome was the number of medication‐related
hospitalisations in high‐risk patients. If patients had multiple
medication‐related hospitalisations, all hospitalisations were included.
Only acute hospitalisations were included, as planned hospitalisations
are rarely related to medication.20
2.7 | Assessment of hospitalisations
We performed a case‐by‐case assessment of all acute admissions,
based on a modified version of the algorithm by Kramer et al.,21 to
identify medication‐related hospitalisations. We applied the following
procedure, in which all assessors were blinded for the corresponding
study groups:
STEP 1: a medical doctor or a senior medical Master student
determined whether the reason(s) for admission could be related to
a known side‐effect of the used medication. Side‐effects with an
incidence of at least 1% according to Dutch standard reference
sources22-24 and side‐effects explicitly described in the discharge
letter were included for further assessment.
STEP 2: An expert duo, consisting of a medical doctor (J.P., V.S.)
and a clinical pharmacist (A.H., P.H., S.H., M.B.) assessed whether
the hospitalisations selected in step 1 were possibly or unlikely to
be medication related. For this assessment, 2 elements were taken
into account: first, whether alternative causes (other than the
suspected medication), such as a pre‐existing clinical condition,
explained the reason for admission; second, the time relationship
between the potential side effect and the start of medication admin-
istration. Admissions that were beyond the scope of the NDPs were
excluded, such as admissions in patients treated for malignancies,
post‐transplantation, patients on renal dialysis and psychiatric
admissions.
STEP 3. Results of step 1 and 2 were compared. In case of
disagreement, consensus meetings with an experienced GP (D.Z., N.
d.W.) and/or clinical pharmacist (A.L.) were arranged. Differences were
resolved in discussion.
STEP 4. Of all cases excluded in step 1, a random 10% sample
was double checked by a medical doctor (V.S.) and a clinical pharma-
cist (A.H.). In case of disagreement about the exclusion, the case
was reassessed. According to a preset protocol, all excluded cases
would be reassessed in case the percentage of disagreement
exceeded 10%.
2.8 | Secondary outcomes
2.8.1 | DBI
The DBI25 measures a patient's total exposure to anticholinergic and
sedative medications, taking medication dosage into account:
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DBI ¼ ∑ D
Dþ δ
 
, with D being the daily medication dose and δ being
the minimum recommended daily dose, we used those stated in Dutch
reference sources.22 We calculated the DBIs at the start and at the
end of the intervention period for each high‐risk patient. A reduction
in DBI of at least 0.5 was considered clinically relevant, as this is the
average effect of stopping 1 anticholinergic or sedative drug.26
2.8.2 | Costs
We calculated direct primary and secondary healthcare costs and total
medication costs, in both the pre and the post periods for each high‐
risk patient, using cost reimbursement data of the major health insur-
ance company. We compared intervention practices with usual care
practices, as in usual care plus practices too few patients were insured
with this company.
2.9 | Sample size
We assumed the annual incidence rate of medication‐related
hospitalisations in the high‐risk population to be 4.5.27 We expected
a 50% reduction of medication‐related hospitalisations.28 To demon-
strate a statistically significant difference between the intervention
and control groups, at least 2850 high‐risk patients needed to be
present in each study group. As the high‐risk population comprises
6.4% of an average general practice in the Netherlands, 45 000
patients were needed for each study group.27 Assuming an average
practice size of 5000 patients, we aimed to include 10 practices
per study group. This was based on a 2‐sided α of 0.05 and a power
(1 – β) of 0.8.8
2.10 | Data analysis
The primary outcome, the number of medication‐related
hospitalisations in high‐risk patients (count data), was analysed with
a Poisson mixed model to compare the intervention and control
groups, with adjusted rate ratios. The model included a random inter-
cept to adjust for clustering at practice level and a residual (i.e. gener-
alised estimating equations type) covariance matrix to account for
patients that were included in both the baseline and intervention
period. The intervention effect was assessed with the interaction
between study group and study period. We adjusted for patients'
age, sex, number of chronically used medications and number of
comorbidities (medications and comorbidities as measured in the
corresponding study period). On practice level, we adjusted for the
degree of urbanisation and socioeconomic status.
In a sensitivity analysis, we excluded those types of medication‐
related hospitalisations that were previously not used in research of
medication‐related hospitalisations (fever/infection/inflammation)
because of an unclear or weak association between medication and
hospitalisation.
The secondary outcome DBI was analysed with a linear mixed
model to compare treatment‐effects between the intervention and
both control groups. A subanalysis was performed excluding patients
with a DBI‐score of 0 at baseline. Costs were split into direct primary
healthcare costs, direct secondary healthcare costs and medication
costs, and analysed with linear mixed models on log‐transformed data
to compare the intervention and usual care group. All models included
elements comparable but somewhat different to the primary outcome
model; for details please see Appendix 1.
All analyses were performed using both SAS software Version 9.4
for Windows and IBM SPSS Statistics for Windows Version 23.0
(Armonk, NY).
2.11 | Ethical considerations
The Medical Ethical Committee of the University Medical Center
Utrecht waived formal medical–ethical assessment (METC protocol
number 13‐432C).
3 | RESULTS
3.1 | Study practices
Ten NDPs were embedded in 10 general practices in the intervention
group. One NDP was unable to finish the training programme and was
withdrawn from the study. This resulted in 9 intervention practices
with an embedded NDP. For the usual care and usual care plus groups,
we approached approximately 125 general practices and included 10
and 6 participating practices, respectively.
The practices in the 3 study arms did not differ in multidisciplinary
composition, professional accreditation status, GP training site or
urbanisation level (Table 1).
The mean proportion of high‐risk patients per practice was highest
in the usual care plus group: 7.4% compared to 5.6 and 6.4% in the
intervention and usual care groups. The mean socioeconomic status
of patients was higher in the intervention practices (0.9) than in the
control practices (0.6; Table 1).
The median number of medication reviews at baseline in the inter-
vention group was 8 per 100 high‐risk patients, compared to 15 in the
usual care group and 3 in the usual care plus group. These medication
reviews were conducted by community pharmacists and/or GPs, and
were part of care as usual.13 No information on the quality of medica-
tion reviews was available. Almost all practices had a high standard of
quality of pharmacotherapy audit meetings.31,32
3.2 | Patients
A total of 11 928 high‐risk patients was included in the analysis. Of
647 patients (5.4%) only pre period data were available, as they were
deregistered from the participating practices because of death (55%),
moving (9%), or for unknown reason (36%). Of 317 patients who
newly registered in the practices during the post period, no pre period
data were available (Figure 1). The number of patients who were
deregistered or newly registered was not equally distributed between
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the study groups. In the intervention, usual care and usual care plus
groups, 3.9, 5.1 and 7.3% of patients were deregistered, and 1.8, 3.9
and 2.1% of patients were newly registered, respectively.
Differences in age and sex distribution between the 3 study groups
were insignificant. The proportion of patients aged 85 years or older
was 13% in the intervention group and 16% in both control groups
(Table 1). The median number of chronically used medications was 6
in all study groups and the median number of registered comorbidities
was 4 in both the intervention and usual care group and 5 in the usual
care plus group.
3.3 | Primary outcome: medication‐related
hospitalisations
In the intervention period, we identified a total of 822 medication‐
related hospitalisations among 11 281 high‐risk patients in the 3 study
groups (Table 2). The adjusted mean rate of medication‐related
hospitalisations was 4.4 per 100 high‐risk patients per year in the
intervention group, 6.4 in the usual care group and 4.2 in the usual care
plus group (Table 3). The adjusted rate ratio for medication‐related
hospitalisations in the intervention group compared to usual care
TABLE 1 Practice and patient characteristics at baseline
Intervention group
(9 practices)
Usual care group
(10 practices)
Usual care plus group
(6 practices)
Practice Practice size
Patients ≥18 years, median (IQR) 8669 (4765–10 689) 5973 (5371–6646) 6907 (4474–13 981)
High‐risk patients, median (IQR) 427 (312–587) 344 (271–501) 523 (285–1087)
Setting and organisation
Degree of urbanisationa, mean ± SD (range) 1.8 ± 1.1 (1–4) 2.1 ± 0.7 (1–3) 2.2 ± 0.8 (1–3)
Socioeconomic statusb, mean ± SD (range) 0.9 ± 1.0 (−1.2–2.2) 0.6 ± 0.9 (−2.1–1.7) 0.6 ± 0.5 (0–1.2)
Healthcare Centre, n (%) 7 (78) 7 (70) 3 (50)
GP training practice, n (%) 8 (89) 7 (70) 4 (67)
Indoor pharmacy, n (%) 6 (67) 6 (60) 4 (67)
Collaborating pharmacies, mean ± SD (range) 1 ± 1 (1–4) 2 ± 1 (1–4) 2 ± 2 (1–5)
Patient High‐risk patients, n 3879 3941 3791
Male sex, n (%) 1703 (44) 1756 (45) 1693 (45)
Age, mean ± SD 75 ± 8 75 ± 8 75 ± 8
Patients <75 years, n (%) 2069 (53) 1901 (48) 1893 (50)
Patients 75–85 years, n (%) 1318 (34) 1414 (36) 1296 (34)
Patients ≥85 years, n (%) 492 (13) 626 (16) 602 (16)
Chronic medications, median (IQR) 6 (5–7) 6 (5–8) 6 (5–8)
Comorbiditiesc, median (IQR) 4 (3–6) 4 (3–6) 5 (3–7)
SD, standard deviation; GP, general practitioner; IQR, interquartile range.
aUsing a 5‐point scale of degree of urbanisation (1 = highly urbanised area, 5 = rural area).29
bData from Dutch Social and Cultural Planning Office, using status scores of zip code area of the general practice (a higher score represents a higher
status).30
cUsing the UK Quality and Outcomes Framework and overview of chronic diseases developed by the Dutch National Institute for Health and
Environment.17,18
FIGURE 1 Flowchart of medication‐related
hospitalisations in the total study population
in both study periods.
*deregistered high‐risk patients in general
practice during the pre period. † newly
registered high‐risk patients in the general
practice after the pre period
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was 0.68 (95% confidence interval [CI] 0.57–0.82) and compared to
usual care plus 1.05 (95% CI 0.73–1.52; Table 3). Of the patients with
a medication‐related hospitalisation, 5% had >1 medication‐related
hospitalisation.
The types of medication‐related hospitalisations and associated
medications are reported in Table 4. Most frequent hospitalisations
were those related to infections, falls and bleeding. Most medication‐
related hospitalisations were associated with a single medication, but
those related to falls and constipation were often associated with a
combination of medications.
The sensitivity analysis excluding medication‐related hospitali-
sations related to infections, showed similar adjusted rate ratios of
the intervention compared to usual care and usual care plus: 0.70
(95% CI 0.55–0.89) and 0.97 (95% CI 0.68–1.39), respectively.
3.4 | Secondary outcomes
3.4.1 | DBI
The DBI scores in all groups did not differ. When comparing the treat-
ment effects on DBI scores per patient with a mixed model, we found
no differences between the intervention group and both usual care
groups (Table 5 and 6). The subanalysis, excluding patients with a
DBI score of 0 in the pre year, did not alter the results.
3.4.2 | Costs
Mixed model comparison of average direct healthcare costs revealed
no differences between the intervention group and usual care group
in primary care costs, secondary care costs and medication costs
(Table 7 and 8). Also, when looking more closely into secondary
healthcare costs related to hospitalisations, we found no differences:
adjusted ratio 0.82 (95% CI 0.64–1.06).
4 | DISCUSSION
This study demonstrates a lower rate of medication‐related
hospitalisations among high‐risk patients in general practices with fully
integrated NDPs compared to usual care. No difference with usual care
plus practices was found. Also, no differences in DBI scores nor in
direct healthcare costs were found. Despite the absence of an effect
on DBI scores and costs, results on medication‐related hospitalisations
suggest that in order to improve medication safety, the current model
of pharmaceutical care provision should be replaced by new concepts
of pharmaceutical care provision, centred around full integration of
pharmaceutical care in medical practice — such as the NDP care
model.
4.1 | Comparison with existing literature
To our knowledge, this is the first study evaluating the effect of NDPs
integrated in general practice on medication‐related hospitalisations.
Studies measuring the impact of such NDP‐led care on relevant clini-
cal patient outcomes are sparse. Lowrie et al. reported no effect of
NDP‐led care on death or hospitalisation in patients with heart fail-
ure.34 Maybe this lack of effect was due to the fact that this interven-
tion had insufficient patient follow‐up. Moreover, NDPs in Lowrie's
study, so‐called non-specialist pharmacists, only received a very short
additional training.
TABLE 2 Unadjusted numbers of medication‐related hospitalisations in high‐risk patients
Study group
Intervention group Usual care group Usual care plus group
Study period Pre Post Pre Post Pre Post
High‐risk population, n 3879 3798 3941 3894 3791 3589
Acute hospitalisations, n (%) 542 (14.0) 584 (15.4) 691 (17.5) 841 (21.6) 517 (13.6) 500 (13.9)
Medication‐related hospitalisations, n (%) 213 (5.5) 230 (6.1) 297 (7.5) 355 (9.1) 204 (5.4) 237 (6.6)
Patients with medication‐related hospitalisations, n (%) 172 (4.4) 187 (4.9) 236 (6.0) 289 (7.4) 166 (4.4) 199 (5.5)
TABLE 3 Adjusted rates and rate ratios of medication‐related hospitalisations in high‐risk patients, per study groupa
Adjusted rate, n medication‐related hospitalisations per 100 high‐risk patients per year
Rate ratio (95% CI)
Post
Intervention group 4.4 Intervention group
Usual care group 6.4 vs usual care group: 0.68 (0.57–0.82)
Usual care plus group 4.2 vs usual care plus group: 1.05 (0.73–1.52)
CI, confidence interval
aAdjusted at patient level for age, sex, number of chronic medications and comorbidities as measured in the corresponding study period; at practice level for
the degree of urbanisation and socioeconomic status; and adjusted for clustering, using a Poisson mixed model. These adjustments resulted in estimates for
an average patient in the total database
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Studies measuring the impact of NDP‐led care on surrogate clinical
outcomes (e.g. glycated haemoglobin, blood pressure and cholesterol
levels) and the quality of medication use (e.g. appropriateness of
prescribing and medication adherence) are more frequent, and gener-
ally demonstrate positive effects.7,35 However, heterogeneity amongst
interventions complicates valid comparison of results. Studies about
TABLE 4 Reason for medication‐related hospitalisation and associated medications, including both pre and post periods
Reason for admissiona n (%) Most associated medications (n)b
Fever/infection/inflammation (e.g.
pneumonia, urinary tract infection)
394 (23) Corticosteroids (377), immunosuppressive drugs (23), sympathicomimetics (19), opiates
(10), diuretics (8), antibiotics (7), antimuscarinics (7), antiepileptics (7), statins (7),
benzodiazepines (7)
Dizziness/collapse/hypotension/
syncopec
352 (21) Beta‐blockers (152), benzodiazepines (98), ACE inhibitors (96), diuretics (81), angiotensin II
receptor blockers (62), antidepressants (54), opiates (53), nitrates (51), calcium channel
blockers (47)
Bleeding (non‐GI; e.g. haematuria,
epistaxis, anaemia)
162 (10) Vitamin K antagonists (102), antiplatelets (74), heparins (10)
Gastrointestinal complication/bleeding
(e.g. ulcer, gastritis, melena)
139 (8) Antiplatelets (87), vitamin K antagonists (71), NSAIDs (12)
Congestive heart failure 122 (7) Beta‐blockers (53), calcium channel blockers (36), diuretics (32), corticosteroids (13), ACE
inhibitors (7), NSAIDs (4)
Arrhythmia (e.g. bradycardia, atrial
fibrillation)
82 (5) Beta‐blockers (40), antiarrhythmics (32), antidepressants (7), ACE inhibitors (7)
Renal insufficiency/electrolyte
imbalance (e.g. hypokalaemia,
hyponatremia)
85 (5) Diuretics (59), ACE‐inhibitors (21), proton‐pump inhibitors (9), angiotensin II receptor
blockers (9), NSAIDs (7)
Nausea/vomiting/diarrhoea/
gastroenteritis
57 (3) Proton‐pump inhibitors (15), opiates (14), antibiotics (13), corticosteroids (8), laxatives (7)
Ileus/constipation 44 (3) Opiates (22), calcium‐channel blockers (20), β‐blockers (13), antidepressants (8), proton‐
pump inhibitors (8)
Chest pain 42 (2) ACE‐inhibitors (25), β‐blockers (7), antiplatelets (5), α‐blockers (4)
Confusion/drowsiness/delirium 32 (2) Opiates (13), dopaminergics (12), benzodiazepines (9), antidepressants (7), antiepileptics (4),
antipsychotics (4)
Hypoglycaemia or hyperglycaemia 30 (2) Insulin (21), oral antihyperglycemics (12)
Other (e.g. cardiovascular events,
dehydration, intoxications)
146 (9) Diuretics (34), corticosteroids (28), dopaminergics (14), antiplatelets (14), ACE inhibitors
(12), vitamin K antagonists (11), opiates (9), β‐blockers (8), digoxin (7), NSAIDs (6),
antiepileptics (6), antidepressants (6), calcium‐channel blockers (6)
ACE, angiotensin‐converting enzyme; GI, gastrointestinal; NSAID, nonsteroidal anti‐inflammatory drug.
aIn 1 medication‐related hospitalisation (total n = 1536), >1 cause could be identified (total n = 1687).
bOne medication‐related hospitalisation (total n = 1536) could be associated with >1 medication (total n = 2750).
cAlso includes patients with a fracture following collapse.
TABLE 5 Unadjusted drug burden indexa per high‐risk patient
Study group
Intervention group Usual care group Usual care plus group
Study period Pre Post Pre Post Pre Post
High‐risk patients, nb 3106 3091 3232 3292 3185 2974
DBI per patient, mean (SD) 0.48 (0.64) 0.50 (0.63) 0.53 (0.63) 0.54 (0.64) 0.78 (0.68) 0.56 (0.67)
DBI categorised, n patients (%)
0 1485 (48) 1425 (46) 1379 (43) 1354 (41) 1331 (42) 1233 (42)
0–1 1158 (37) 1173 (38) 1311 (41) 1342 (41) 1218 (38) 1177 (40)
>1 463 (15) 493 (16) 542 (17) 596 (18) 636 (20) 564 (19)
DBI, drug burden index; SD, standard deviation
aIncluding all chronically used anticholinergic or sedative medications, excluding ATC‐D, ATC‐L, ATC‐P, ATC‐S and ATC‐V.33
bDue to missing data, not all high‐risk patients as included in the primary outcome analyses were included here.
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specific interventions and targeting specific medications or specific
conditions are more likely to show positive results than studies on
complex interventions targeting multiple medications and/or multiple
conditions.36-40 We think, however, that comprehensive medication
therapy management is typically needed in high‐risk patients, in whom
multiple medications and conditions impact each other.41
Measuring clinical effects of such NDP‐led comprehensive medica-
tion therapy management, a complex intervention, is challenging. Full
integration of NDPs in general practice seems key to enlarge effect
on pharmaceutical care outcomes.35 Also, taking integral responsibility
for the patient's pharmacotherapy and providing follow‐up consulta-
tions to monitor the patient is recognised to be essential.42,43 Further-
more, education is needed to equip the NDPs with the necessary
clinical knowledge, consultation skills and experience to work as part
of the multidisciplinary general practice team.44,45 We believe that
these 3 aspects (the NDPs being fully integrated in the team, taking
integral responsibility for the patient's pharmacotherapy and partici-
pating in additional education) enable the NDPs to significantly
improve the quality of pharmaceutical care.
4.2 | Interpretation of results
Differences in rates of medication‐related hospitalisations should be
interpreted with caution. We found a stronger increase of total acute
hospitalisations in the usual care group than in the other 2 groups,
when comparing the intervention year to the baseline year (see
Table 2). Even after detailed analysis of the data, we could not explain
this difference. It might be related to the practice population, or simply
to chance. Nonetheless, as the number of total acute hospitalisations
is closely related to the primary outcome, this quite marked increase
of hospitalisations in the usual care group could have influenced (part
of) the intervention effect.
Interestingly, medication‐related hospitalisation outcomes in inter-
vention and usual care plus practices did not differ. We think that this
is related to characteristics of the usual care plus practices that we did
not take into account at the time of inclusion. The additional training
in performing clinical medication review (the inclusion criterion for
usual care plus) appeared to be no standalone feature but rather an
expression of an already highly integrated pharmaceutical care‐model.
In the usual care plus practices, there was a strong pre‐existing collab-
oration between GPs and community pharmacists, with joint informa-
tion systems, regular (in)formal face‐to‐face meetings between GPs
and pharmacists and a common focus upon medication therapy
management. The main difference with the NDP‐intervention prac-
tices was that in these practices NDPs were formally co‐located in
general practices and extensively trained in clinical knowledge, skills
and communication.12
Regarding the DBI, we found no difference between the interven-
tion and control groups. When interpreting this finding, several issues
TABLE 7 Crude costs per high‐risk patient, in euros
Study group
Intervention group Usual care group
Study period Pre Post Pre Post
High‐risk patients, na 2525 2574 2553 2474
Primary care costsb, median (IQR) 403 (232–560) 428 (246–602) 422 (233–581) 364 (228–560)
Secondary care costsc, median (IQR) 977 (188–3359) 840 (122–3249) 1148 (191–4269) 843 (93–3545)
Medication costsd, median (IQR) 841 (441–1581) 868 (450–1479) 857 (435–1532) 749 (400–1383)
IQR, interquartile range
aDue to using a different data source for these analyses, not all high‐risk patients included in the primary outcome analyses were included here.
bPrimary healthcare costs included consultations and home visits by GPs and general practice‐based nurse specialists, additional proceedings, module fees
and registration fees.
cSecondary healthcare costs included hospital care as remunerated in DOTs (these are defined remunerations for combinations of diagnoses and treat-
ments, that particularly last longer than 1 day but maximally a year). Only those DOTs starting during the study period were included.
dMedication costs included medications prescribed both in primary and secondary care.
TABLE 8 Adjusted ratios of average healthcare costs in high‐risk
patientsa
Ratio of healthcare costs in intervention group
vs usual care group (95% confidence interval) P‐value
Primary care costs 1.08 (0.99–1.17) .073
Secondary care costs 0.92 (0.65–1.29) .622
Medication costs 1.04 (0.98–1.10) .172
aUsing linear mixed models, see Appendix 1.
TABLE 6 Adjusted treatment effect on lowering drug burden index
in high‐risk patientsa
Comparison of treatment effects
(95% confidence interval) P‐value
Intervention group vs usual
care group
−0.02 (−0.07–0.02) .291
Intervention group vs usual
care plus group
−0.01 (−0.06–0.04) .609
aUsing a linear mixed model, see Appendix 1.
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should be considered. First, due to technical difficulties in extracting
the medications used per patient, we had missing data on DBI scores
in both the pre and post periods (in 17% and 18% of high‐risk patients,
respectively). Such large proportions of missing data put the compari-
son of DBIs at risk, minimising chances to find small differences. Sec-
ond, we included all high‐risk patients in the analysis, while not all
patients received the intervention by the NDP, possibly diluting a
potential effect.
Few studies used DBI‐scores to evaluate effects of NDP‐led
interventions. A study in the Netherlands, researching effects of an
intervention by a community pharmacist in collaboration with a GP,
did also not find an effect on DBI scores — even while this interven-
tion was specifically tailored on improving the DBI.26 On the contrary,
2 studies from Australia did find positive effects on DBI‐scores follow-
ing medication therapy management interventions by pharmacists in
collaboration with GPs.46,47 However, in 1 of these studies,46 total
group effects were researched instead of an in‐patient lowering of
DBIs. The other study47 did report an in‐patient decrease of DBI‐
scores, but this reduction of 0.12 did not meet the 0.5 reduction we
consider clinically relevant. So, effect of NDP‐led care on reducing
DBI‐scores remains subject of research.
Regarding costs, we hypothesised in advance to find a shift in costs
from secondary to primary care in intervention practices compared to
usual care, as we expected fewer medication‐related hospitalisations.
However, the cost comparison did not confirm this hypothesis. This
might be related to the fact that we used cost reimbursement data
of a health insurance company as the basis of the calculations. We
could not individually link these data to our general practice
database, hence individual cost comparison of medication‐related
hospitalisations was impossible. In addition, although such cost reim-
bursement data reflect actual expenditures, they do not precisely
cover the actual provided care — at least not regarding secondary
healthcare costs. In the Netherlands, secondary care is remunerated
through so‐called DOTs (defined remunerations for combinations of
diagnoses and treatments), instead of through individual medical
actions. Hence, any existing differences might be blurred, as remuner-
ation data lack precision. This idea, that in our study actual existing
differences might be blurred, is further supported by 2 studies
reporting an (expected) reduction of costs after introduction of an
NDP in primary care in the UK, based on measurements of actual used
care‐elements.48,49 Based only on prescribing changes, Snell et al.48
expected reductions in costs of about £90 (equivalent to about €99)
per high‐risk patient per year (resulting from a total of £46,000 costs
savings and £9000 additionally spent on medication after introduction
of NDPs in primary care). Including total primary care costs and taking
investments into account, Bush et al.49 reported that every £1
invested in NDP‐care, would result in £4.73 savings; in total, saving
on average £3052 per GP practice per month (about €3364). Few
studies reporting on cost‐effects of NDP‐led care suggest that NDP‐
led care might reduce costs. We did not find such results, maybe
due to the fact that we used cost reimbursement data instead of mea-
surements of actual used care‐elements. Future research including
cost‐effectiveness analyses may provide more insight.
4.3 | Strengths and limitations
This study has several strengths.We covered a large patient population
with in total 11 928 registered high‐risk patients. The intervention was
multifaceted, tailored to the needs of each general practice and per-
formed in a real‐life setting. We used a structured methodology to
systematically identify medication‐related hospitalisations (assessment
by a multidisciplinary team, consensus meetings with experts and
cross‐checking of data) to limit the risk of subjectivity in judgement.
This study also has several limitations. The fact that we chose not to
randomise puts the comparison at risk of bias, even though we
corrected for several relevant baseline differences. We think, however,
that randomisation would have put optimal performance of the NDPs
at risk. A second limitation concerns the sample size calculation of the
study. During our study, a new study reported an increased prevalence
of medication‐related hospitalisations: 10.4%2 instead of the 4.5%28
we used in our original calculations. In addition, the original sample size
calculation was not adjusted for clustering. Future research should take
these 2 elements into account. Third, regarding the primary outcome,
the hospitalisations we identified were possibly medication‐related,
including various levels of certainty about the causality. To assess
definite causality (if that is even possible), data including interviews with
involved doctors, pharmacists and patients would have been
necessary.50 In addition, we could not measure preventability of the
medication‐related hospitalisations due to the nature of available data.
Fourth, flaws in the electronic medical records extraction resulted in
the omission of an unknown number of deceased patients in our
database. As the number of high‐risk patients is the numerator in our
primary outcome, these missing data may influence the absolute
rates of medication‐related hospitalisations among elderly with
polypharmacy. However, as data collection was similar in all study
groups, these missing data probably did not affect the between‐group
comparison. Fifth, we included all high‐risk patients registered in the
participating practices, instead of only patients who had a clinical med-
ication review or consultation with the NDP. This might have diluted
the measured effect. Last, the intervention period lasted only a year.
Even though we added in advance a 3‐month start‐up period, this year
might have been too short to show the full potential of the intervention.
4.4 | Future research
Integration seems key to improve the quality of pharmaceutical care.
This may either be done by introduction of the NDP, or by developing
more usual care plus practices. The latter would involve investment in
existing infrastructure and collaboration, which is likely to be a time
consuming and nontransparent improvement process. In contrast,
the integration of an NDP in general practice is a well described
organisational intervention with a potentially rapid implementation
process. Cost‐effectiveness of both models should be investigated
and implementation research should be continued. An intervention
study with matched control patients could provide more insight into
the effects of NDP‐led care.
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5 | CONCLUSION
In practices with NDP‐led care, we found a lower rate of medication‐
related hospitalisations compared to usual care. No difference with
usual care plus was found. High‐risk patients will benefit most from
integrated pharmaceutical care. Full integration of an NDP in clinical
practice, adequate training and integral responsibility are key condi-
tions of success for this new concept of pharmaceutical care provision.
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